StockData
Galectin Therapeutics Inc logo

Galectin Therapeutics Inc (GALT) stock

GALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$2.91−0.11 (-3.64%)

Close on Nov 17, 2026Market cap $293.47MP/E –Yield –

Galectin Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

No gross margin figures for Galectin Therapeutics

Galectin Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Galectin Therapeutics figures

See a number that looks wrong?